Scinai Immunotherapeutics Ltd (SCNI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.164x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.29 Million) by net assets ($7.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scinai Immunotherapeutics Ltd (SCNI) defensive interval to measure how many days the company can operate on defensive assets alone.
Scinai Immunotherapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Modiin Energy-Limited Partnership
TA:MDIN-L
|
0.177x |
|
NamR SA
PA:ALNMR
|
-0.280x |
|
Eason Technology Limited
NYSE MKT:DXF
|
0.000x |
|
ULTRA LITHIUM
F:QFB
|
-0.007x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
LIQUID AVATAR TECHNO.INC.
F:4T5
|
N/A |
|
Univa Foods Limited
NSE:UNIVAFOODS
|
-0.001x |
|
Hydro Exploitations SA
PA:MLHYE
|
N/A |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Scinai Immunotherapeutics Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.10 Million | $-6.03 Million | -0.744x | -17.22% |
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -252.16% |
| 2020-12-31 | $-4.54 Million | $-22.57 Million | 4.970x | +319.55% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more